Patient demographics, disease- and transplant-related factors by JAK2V617Fmutation status
| . | Mutation negative N = 362 . | Mutation positive N = 562 . | P . |
|---|---|---|---|
| Recipient age (y) | .001 | ||
| <40 | 31 (8.56) | 21 (3.74) | |
| 40 to <50 | 58 (16.02) | 67 (11.92) | |
| 50 to <60 | 138 (38.12) | 218 (38.79) | |
| ≥60 | 135 (37.29) | 256 (45.55) | |
| Recipient sex | .10 | ||
| Male | 223 (61.60) | 316 (56.23) | |
| Female | 139 (38.40) | 246 (43.77) | |
| KPS | .32 | ||
| <90 | 145 (40.06) | 243 (43.24) | |
| 90-100 | 205 (56.63) | 308 (54.80) | |
| Missing | 12 (3.31) | 11 (1.96) | |
| Disease subtype | |||
| Primary | 269 (74.31) | 365 (64.95) | <.0001 |
| PPV-MF | 4 (1.10) | 131 (23.31) | |
| PET-MF | 89 (24.59) | 66 (11.74) | |
| Conditioning intensity | .02 | ||
| Myeloablative | 186 (51.38) | 245 (43.59) | |
| Reduced intensity/nonmyeloablative | 176 (48.62) | 317 (54.41) | |
| Conditioning regimen | .0003 | ||
| Flu + Bu ± other | 147 (40.61) | 261 (46.44) | |
| Flu + Mel ± other | 82 (22.65) | 167 (29.72) | |
| Flu + TBI ± other | 31 (8.56) | 35 (6.23) | |
| Others7 | 102 (28.18) | 99 (17.62) | |
| GVHD prophylaxis | .19 | ||
| CNI + MMF ± others | 68 (18.78) | 134 (23.84) | |
| CNI + MTX ± others | 224 (61.88) | 327 (58.19) | |
| Others | 70 (19.34) | 101 (17.97) | |
| DIPSS at transplant | .21 | ||
| Low | 26 (7.18) | 46 (8.19) | |
| Intermediate-1 | 74 (20.44) | 138 (24.56) | |
| Intermediate-2/high | 112 (30.94) | 142 (25.27) | |
| Missing | 150 (41.44) | 236 (41.99) | |
| Splenectomy before HCT | .30 | ||
| No | 185 (51.10) | 265 (47.15) | |
| Yes | 4 (1.10) | 12 (2.14) | |
| Unknown | 173 (47.79) | 285 (50.71) | |
| Time between diagnosis and HCT (mo) | .38 | ||
| <12 | 128 (35.56) | 185 (33.27) | |
| 12 to <24 | 58 (16.11) | 74 (13.31) | |
| 24 to <72 | 76 (21.11) | 139 (25.00) | |
| ≥72 | 98 (27.22) | 158 (28.42) | |
| Donor-recipient CMV serostatus | .68 | ||
| Positive-positive | 85 (23.48) | 150 (26.69) | |
| Positive-negative | 59 (16.30) | 76 (13.52) | |
| Negative-positive | 87 (24.03) | 141 (25.09) | |
| Negative-negative | 125 (34.53) | 186 (33.10) | |
| Missing | 6 (1.66) | 9 (1.60) | |
| Donor type | .41 | ||
| Unrelated | 304 (83.98) | 483 (85.94) | |
| Related | 58 (16.02) | 79 (14.06) | |
| Cytogenetics at transplant | .46 | ||
| Favorable normal | 110 (30.39) | 171 (30.43) | |
| Favorable other | 58 (16.02) | 70 (12.46) | |
| Adverse | 54 (14.92) | 86 (15.30) | |
| Missing | 140 (38.67) | 235 (41.82) | |
| Stem cell source | .31 | ||
| Bone marrow | 43 (11.88) | 55 (9.79) | |
| Peripheral blood | 319 (88.12) | 507 (90.21) | |
| Year at transplant | .65 | ||
| 2000-2004 | 22 (6.08) | 40 (7.12) | |
| 2005-2009 | 79 (21.82) | 111 (19.75) | |
| 2010-2016 | 261 (72.10) | 411 (73.13) |
| . | Mutation negative N = 362 . | Mutation positive N = 562 . | P . |
|---|---|---|---|
| Recipient age (y) | .001 | ||
| <40 | 31 (8.56) | 21 (3.74) | |
| 40 to <50 | 58 (16.02) | 67 (11.92) | |
| 50 to <60 | 138 (38.12) | 218 (38.79) | |
| ≥60 | 135 (37.29) | 256 (45.55) | |
| Recipient sex | .10 | ||
| Male | 223 (61.60) | 316 (56.23) | |
| Female | 139 (38.40) | 246 (43.77) | |
| KPS | .32 | ||
| <90 | 145 (40.06) | 243 (43.24) | |
| 90-100 | 205 (56.63) | 308 (54.80) | |
| Missing | 12 (3.31) | 11 (1.96) | |
| Disease subtype | |||
| Primary | 269 (74.31) | 365 (64.95) | <.0001 |
| PPV-MF | 4 (1.10) | 131 (23.31) | |
| PET-MF | 89 (24.59) | 66 (11.74) | |
| Conditioning intensity | .02 | ||
| Myeloablative | 186 (51.38) | 245 (43.59) | |
| Reduced intensity/nonmyeloablative | 176 (48.62) | 317 (54.41) | |
| Conditioning regimen | .0003 | ||
| Flu + Bu ± other | 147 (40.61) | 261 (46.44) | |
| Flu + Mel ± other | 82 (22.65) | 167 (29.72) | |
| Flu + TBI ± other | 31 (8.56) | 35 (6.23) | |
| Others7 | 102 (28.18) | 99 (17.62) | |
| GVHD prophylaxis | .19 | ||
| CNI + MMF ± others | 68 (18.78) | 134 (23.84) | |
| CNI + MTX ± others | 224 (61.88) | 327 (58.19) | |
| Others | 70 (19.34) | 101 (17.97) | |
| DIPSS at transplant | .21 | ||
| Low | 26 (7.18) | 46 (8.19) | |
| Intermediate-1 | 74 (20.44) | 138 (24.56) | |
| Intermediate-2/high | 112 (30.94) | 142 (25.27) | |
| Missing | 150 (41.44) | 236 (41.99) | |
| Splenectomy before HCT | .30 | ||
| No | 185 (51.10) | 265 (47.15) | |
| Yes | 4 (1.10) | 12 (2.14) | |
| Unknown | 173 (47.79) | 285 (50.71) | |
| Time between diagnosis and HCT (mo) | .38 | ||
| <12 | 128 (35.56) | 185 (33.27) | |
| 12 to <24 | 58 (16.11) | 74 (13.31) | |
| 24 to <72 | 76 (21.11) | 139 (25.00) | |
| ≥72 | 98 (27.22) | 158 (28.42) | |
| Donor-recipient CMV serostatus | .68 | ||
| Positive-positive | 85 (23.48) | 150 (26.69) | |
| Positive-negative | 59 (16.30) | 76 (13.52) | |
| Negative-positive | 87 (24.03) | 141 (25.09) | |
| Negative-negative | 125 (34.53) | 186 (33.10) | |
| Missing | 6 (1.66) | 9 (1.60) | |
| Donor type | .41 | ||
| Unrelated | 304 (83.98) | 483 (85.94) | |
| Related | 58 (16.02) | 79 (14.06) | |
| Cytogenetics at transplant | .46 | ||
| Favorable normal | 110 (30.39) | 171 (30.43) | |
| Favorable other | 58 (16.02) | 70 (12.46) | |
| Adverse | 54 (14.92) | 86 (15.30) | |
| Missing | 140 (38.67) | 235 (41.82) | |
| Stem cell source | .31 | ||
| Bone marrow | 43 (11.88) | 55 (9.79) | |
| Peripheral blood | 319 (88.12) | 507 (90.21) | |
| Year at transplant | .65 | ||
| 2000-2004 | 22 (6.08) | 40 (7.12) | |
| 2005-2009 | 79 (21.82) | 111 (19.75) | |
| 2010-2016 | 261 (72.10) | 411 (73.13) |
Bu, Busulfan; CMV, cytomegalovirus; CNI, calcineurin inhibitor; Flu, fludarabine; GVHD, graft-versus-host disease; KPS, Karnofsky Performance Status; Mel, melphalan; MMF, mycophenolate mofetil; MTX: methotrexate; TBI, total body irradiation.